phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in patients with peripheral artery disease and claudication Brass EP, Cooper LT, Morgan RE, et al (Harbor-UCLA Ctr for Clinical Pharmacology,…